Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Pleurectomy/Decortication Followed By Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

Status: Recruiting
Phase: Phase 2
Diagnosis: Lung Cancer
NCT ID: NCT00715611 (View complete trial on
DFCI Protocol ID: 16-372


For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has many side effects that are often severe including damage to the lung (pneumonitis). There is a new radiation technique using Intensity Modulated Radiation Therapy (IMRT) that has been shown to reduce many of the side effects of standard radiation therapy. This type of radiation therapy specifically targets the lining of the lung, where you have your cancer, and reduces the risk of damaging the lung itself. The purpose of this study is to test the safety and implementation of standard pleurectomy/decortication (removal of the surface lining of the lung) performed at other centers. Patients will undergo pleurectomy/decortication followed by chemotherapy then hemithoracic pleural IMRT to the pleura in patients with malignant pleural mesothelioma.


Conducting Institutions:
Brigham and Women's Hospital, Dana-Farber Cancer Institute

Overall PI:
Raymond Mak, MD, Dana Farber Cancer Institute

Site-responsible Investigators:

Dana-Farber Cancer Institute: Bryan Marion,

Eligibility Criteria

Inclusion Criteria: - Provide written informed consent to participate on the study - Patients must have a pathologically confirmed diagnosis either at MSKCC or at the participating site of stage I-III malignant pleural mesothelioma amenable to P/D. - Epithelioid or biphasic histology subtype - No evidence of metastatic disease. - Patient age ≥ 18 years but ≤ 80 years at the time of consent. - Karnofsky performance status ≥ 80% - Pulmonary Function Tests: 1. FEV1 ≥ 35% (corrected for Hgb) of predicted postoperative (ppoFEV1) (as if the patient underwent a pneumonectomy) based on the following formula using the quantitative V/Q scan: °Predicted post-resection FEV1 = FEV1 x % perfusion to uninvolved lung from the quantitative V/Q scan report - DLCO > 40% predicted (corrected for Hgb) - Patient must have adequate organ function as indicated by the following laboratory values: 1. Absolute neutrophil count ≥1.5 K/mcL 2. Platelets ≥100 K/mcL 3. Serum total bilirubin ≤ 1.5 X ULN 4. AST (SGOT) or ALT (SGPT) ≤ 3.0 X ULN - In cases of concern about renal toxicity from chemotherapy, an optional nuclear medicine kidney function scan may be performed prior to radiation therapy to determine the functional contribution of each kidney. - Reassessment after P/D: Confirmation of resection status postoperatively, prior to proceeding with adjuvant chemotherapy and pleural IMRT Exclusion Criteria: - Sarcomatoid or desmoplastic histology - Continuous oxygen use - Prior nephrectomy on the contralateral side of MPM - Prior systemic therapy (e.g. chemotherapy/biological agents) for mesothelioma - Prior intrapleural therapy (except pleurodesis) or intrapleural therapy at the time of P/D - Prior thoracic radiation therapy preventing hemithoracic pleural IMRT - Bulky disease in the fissure preventing lung-sparing pleural IMRT - Patients undergoing extrapleural pneumonectomy - Patients with an active infection that require systemic antibiotics, antiviral, or antifungal treatments - Patients with a concurrent active malignancy (except squamous or basal cell carcinoma of the skin) - Patients with serious unstable medical illness - Presence of third space fluid that cannot be controlled by drainage - For patients who develop or have baseline clinically significant pleural effusions before or during initiation of pemetrexed therapy; consideration should be given to drain the effusion prior to dosing - No acute congestive heart failure - Pregnant or lactating women - Men or women not using effective contraception Reproductive risks Patients should not become pregnant or father a baby while on this study because the drugs in this study can affect an unborn baby. Women should not breast-feed a baby while on this study. Women of childbearing age will be counseled to use birth control while on this study.
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online